Economical Aspects of Dementia

Handbook of Clinical Neurology

Volumn 89, Issue , 2008, Pages 137-146

  Wimo, Anders ^a   Winblad, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COGNITIVE DEFECT; COST OF ILLNESS; DEMENTIA; ECONOMICS; HEALTH CARE COST; HUMAN; REVIEW; STATISTICAL MODEL;

COGNITION DISORDERS; COST OF ILLNESS; DEMENTIA; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC;

EID: 66049113196     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01213-4     Document Type: Review

References (89)

1. Bergner M., Bobbitt R.A., Carter W.B., et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19 (1981) 787-805
2. Bowling A. Measuring Health. A review of quality of life measurement scales (1995), Open University Press, Milton Keynes
3. Brod M., Stewart A.L., Sands L., et al. Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL). Gerontologist 39 (1999) 25-35
4. Buxton M.J., Drummond M.F., Van Hout B.A., et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6 (1997) 217-227
5. Caro J.J., Salas M., Ward A., et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 14 (2002) 84-89
6. Cavallo M.C., and Fattore G. The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 11 (1997) 184-190
7. Clipp E.C., and Moore M.J. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 58 (1995) 228-236
8. Cohen-Mansfield J., Marx M.S., and Rosenthal A.S. A description of agitation in a nursing home. J Gerontol (Medical Sciences) 44 (1989) M77-M84
9. Coucill W., Bryan S., Bentham P., et al. EQ-5D in patients with dementia: an investigation of inter-rater agreement. Med Care 39 (2001) 760-771
10. Courtney C., Farrell D., Gray R., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 (2004) 2105-2115
11. Cummings J.L., Mega M., Gray K., et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
12. Davis K.L., Marin D.B., Kane R., et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 12 (1997) 978-988
13. Deeken J.F., Taylor K.L., Mangan P., et al. Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. J Pain Symptom Manage 26 (2003) 922-953
14. Donaldson C., Mugford M., and Vale L. Evidence-based health economics (2002), BMJ Books
15. Drummond M.F., O'Brien B., Stoddart G.L., et al. Methods for the economic evaluation of health care programmes (1997), Oxford University Press, Oxford
16. Ernst R.L., and Hay J.W. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 84 (1994) 1261-1264
17. Feldman H., Gauthier S., Hecker J., et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63 (2004) 644-650
18. Fenn P., and Gray A. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach. Pharmacoeconomics 16 (1999) 165-174
19. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
20. François C., Sintonen H., Sulkava R., et al. Cost effectiveness of memantine on moderately severe to severe Alzheimer's disease. A Markov model in Finland. Clin Drug Invest 24 (2004) 373-384
21. Fratiglioni L., Viitanen M., Backman L., et al. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 11 (1992) 29-36
22. Fratiglioni L., and Roccas W.A. Epidemiology of dementia. In: Boller F., et al. (Ed). Handbook of Neuropsychology. 2nd edn (2001), Amsterdam, Elsevier 193-215
23. Garfield F.B., Getsios D., Caro J.J., et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD). Treatment with Galantamine in Sweden. Pharmacoeconomics 20 (2002) 629-637
24. Gauthier S., Gelinas I., and Gauthier L. Functional disability in Alzheimer's disease. Int. Psychogeriatr 9 (1997) 163-165
25. Geldmacher D.S., Provenzano G., McRae T., et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51 (2003) 937-944
26. Getsios D., Caro J.J., Caro G., et al. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 57 (2001) 972-978
27. Guy W. Clinical global impressions (cgi), US department of Health and Human Services PHS, Alcohol Drug Abuse, Mental Health Administration, NIMH Psychology Research Branch. ECDU Assessment manual for psychopharmacology (1979) 218-222 Rockville, MD
28. Hauber A.B., Gnanasakthy A., and Mauskopf J.A. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 22 (2000) 439-451
29. Hughes C.P., Berg L., Danziger W.L., et al. A new clinical scale for the staging of dementia. Br J Psychiatry 140 (1982) 566-572
30. Ikeda S., Yamada Y., and Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 13 (2002) 33-39
31. Jones R.W., McCrone P., and Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 21 (2004) 607-620
32. Jonsson L., Lindgren P., Wimo A., et al. Costs of Mini Mental State Examination-related cognitive impairment. Pharmacoeconomics 16 (1999) 409-416
33. Jonsson L., Lindgren P., Wimo A., et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 21 (1999) 1230-1240
34. Jonsson L., Jonsson B., Wimo A., et al. Second International Pharmacoeconomic Conference on Alzheimer's Disease. Alzheimer Dis Assoc Disord 14 (2000) 137-140
35. Karlsson G., Jonsson B., Wimo A., et al. Methodological issues in health economics of dementia. In: Wimo A., Jonsson B., Karlsson G., and Winblad B. (Eds). Health economics of dementia (1998), John Wiley & Sons, London 161-169
36. Katz S., Ford A.B., Moskowitz R.B., et al. A standardized measure of biological and psychosocial function. JAMA 185 (1963) 914-919
37. Kerner D.N., Patterson T.L., Grant I., et al. Validity of the Quality of Well-Being Scale for patients with Alzheimer's disease. J Aging Health 10 (1998) 44-61
38. Klarin I., Fastbom J., and Wimo A. A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. Pharmacoepidemiol Drug Saf 12 (2003) 669-678
39. Knopman D., Schneider L., Davis K., et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 47 (1996) 166-177
40. Kronborg Andersen C., Sogaard J., Hansen E., et al. The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 10 (1999) 295-304
41. Lawton M.P., and Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9 (1969) 179-186
42. Logsdon R.G., Gibbons L.E., McCurry S.M., et al. Assessing quality of life in older adults with cognitive impairment. Psychosom Med 64 (2002) 510-519
43. Lowin A., Knapp M., and McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry 16 (2001) 1143-1148
44. Martikainen J., Valtonen H., and Pirttila T. Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ 5 (2004) 136-142
45. McDaid D. Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges. Int J Geriatr Psychiatry 16 (2001) 400-405
46. Migliaccio-Walle K., Getsios D., Caro J.J., et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 25 (2003) 1806-1825
47. Mohide E.A., Torrance G.W., Streiner D.L., et al. Measuring the wellbeing of family caregivers using the time trade-off technique. J Clin Epidemiol 41 (1988) 475-482
48. Moise P., Schwarzinger M., Umd M., et al. Dementia care in 9 OECD countries. A comparative analysis (2004), OECD, Paris OECD Health Working Papers No 13
49. Neumann P.J., Hermann R.C., Kuntz K.M., et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52 (1999) 1138-1145
50. Neumann P.J., Sandberg E.A., Araki S.S., et al. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making 20 (2000) 413-422
51. Nocera S., Bonato D., and Telser H. The contingency of contingent valuation. How much are people willing to pay against Alzheimer's disease?. Int J Health Care Finance Econ 2 (2002) 219-240
52. Nordberg G., von Strauss E., Kareholt I., et al. The amount of informal and formal care among non-demented and demented elderly persons: results from a Swedish population-based study. Int J Geriatr Psychiatry 20 (2005) 862-871
53. O'Brien B.J., Goeree R., Hux M., et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 47 (1999) 570-578
54. Ostbye T., and Crosse E. Net economic costs of dementia in Canada. CMAJ 151 (1994) 1457-1464
55. Reisberg B., Ferris S.H., de Leon M.J., et al. Global deterioration scale (GDS). Psychopharmacol Bull 24 (1988) 661-663
56. Reisberg B., Auer S.R., and Monteiro I.M. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 8 (1996) 301-308 discussion 351-354
57. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
58. Salek S.S., Walker M.D., and Bayer A.J. A review of quality of life in Alzheimer's disease. Part 2: Issues in assessing drug effects. Pharmacoeconomics 14 (1998) 613-627
59. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (1997) S22-S32
60. Selai C.E., Elstner K., and Trimble M.R. Quality of life pre and post epilepsy surgery. Epilepsy Res 38 (2000) 67-74
61. Selai C., Vaughan A., Harvey R.J., et al. Using the QOL-AD in the UK. Int J Geriatr Psychiatry 16 (2001) 537-538
62. Siegel J.E., Torrance G.W., Russell L.B., et al. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics 11 (1997) 159-168
63. Sonnenberg F.A., and Leventhal E.A. Modeling disease progression with Markov models. In: Wimo A., Jonsson B., Karlsson G., and Winblad B. (Eds). Health economics of dementia (1998), John Wiley & Sons, London 171-196
64. Spilker B. Quality of life and pharmacoeconomics in clinical trials (1996), Lippincott-Raven, Philadelphia
65. Stewart A., and Brod M. Measuring health related quality of life in older and demented people. In: Spilker B. (Ed). Quality of life and pharmacoeconomics in clinical trials (1996), Lippincott-Raven, Philadelphia 819-830
66. Stewart A., Phillips R., and Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 13 (1998) 445-453
67. Torrance G. Designing and conducting cost-utility analysis. In: Spilker B. (Ed). Quality of life and pharmacoeconomics in clinical trials (1996), Lippincott-Raven, Philadelphia 1105-1121
68. Torrance G.W. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 3 (1997) S8-S20
69. Torrance G.W., Feeny D.H., Furlong W.J., et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 34 (1996) 702-722
70. Tsuchiya A., Dolan P., and Shaw R. Measuring people's preferences regarding ageism in health: some methodological issues and some fresh evidence. Soc Sci Med 57 (2003) 687-696
71. UN World population prospects. The 1998 revision. World population 1950-2050 (1998), United Nations, New York
72. van den Berg B., Brouwer W.B., and Koopmanschap M.A. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ 5 (2004) 36-45
73. Walker M.D., Salek S.S., and Bayer A.J. A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact. Pharmacoeconomics 14 (1998) 499-530
74. Ward A., Caro J.J., Getsios D., et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 18 (2003) 740-747
75. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
76. Wimo A. Health economic aspects. In: Sbu (Ed). Dementia care-is there any evidence based knowledge (in Swedish) (2004), Gothenburg, Sweden
77. Wimo A., and Jonsson L. Demenssjukdomarnas samhällskostnader (The societal costs of dementia) (in Swedish) (2001), Socialstyrelsen (The National Board of Wealth and Health care), Stockholm
78. Wimo A., and Winblad B. Resource utilisation in dementia: RUD Lite. Brain Aging 3 (2003) 48-59
79. Wimo A., Wallin J.O., Lundgren K., et al. Impact of day care on dementia patients-costs, well-being and relatives' views. Fam Pract 7 (1990) 279-287
80. Wimo A., Mattsson B., Krakau I., et al. Cost-effectiveness analysis of day care for patients with dementia disorders. Health Econ 3 (1994) 395-404
81. Wimo A., Mattson B., Krakau I., et al. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 11 (1995) 49-65
82. Wimo A., Jonsson B., Karlsson G., et al. The Health Economics of Dementia (1998), John Wiley & Sons, London
83. Wimo A., Nordberg G., Jansson W., et al. Assessment of informal services to demented people with the RUD instrument. Int J Geriatr Psychiatry 15 (2000) 969-971
84. Wimo A., von Strauss E., Nordberg G., et al. Time spent on informal and formal care giving for persons with dementia in Sweden. Health Policy 61 (2002) 255-268
85. Wimo A., Winblad B., Aguero Torres H., et al. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17 (2003) 63-67
86. Wimo A., Winblad B., Engedal K., et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15 (2003) 44-54
87. Wimo A., Winblad B., Stöffler A., et al. Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21 (2003) 327-340
88. Winblad B., Hill S., Beermann B., et al. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 11 (1997) 39-45
89. Zarit S.H., Reever K.E., and Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 20 (1980) 649-655